Results 191 to 200 of about 1,093,896 (249)

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

Cancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source

RETRACTION: Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison. [PDF]

J Dermatol
europepmc   +1 more source

Association of Janus kinase inhibitors with reduced depression in alopecia areata. [PDF]

J Eur Acad Dermatol Venereol
Ho CY, Wu HL, Dai YX, Shih YH, Tai YH.
europepmc   +1 more source

PABPC1 in Cancer: From a Translational Housekeeper to a Stress‐Responsive Regulatory Hub

Cancer Science, EarlyView.
PABPC1 shifts from a translational housekeeper to a stress‐responsive oncogenic hub via phase separation, PTMs, and non‐coding RNA crosstalk, selectively driving oncogene translation and therapy resistance in cancer. ABSTRACT PABPC1, long recognized as a constitutive translational housekeeper, has emerged as a stress‐responsive translational ...
Cuiwei Zhang, Ye Zhu, Wenbo Long
wiley   +1 more source

The use of Janus kinase inhibitors to treat noninfectious uveitis. [PDF]

Eye (Lond)
Beckman M, Srivastava SK, Lowder CY, Baynes K, Lowe A, Sharma S.   +5 more
europepmc   +1 more source

NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis

British Journal of Haematology, EarlyView.
R. Van Dijck, M. ter Borg, B. van der Holt, A. E. C. Broers, M. D. Hazenberg, J. J. Cornelissen, N. P. M. Schaap, E. de Pater, P. A. W. te Boekhorst   +8 more
wiley   +1 more source

A20 Inhibits IFN‐γ Signaling in Hepatocellular Carcinoma Cells by Binding to STAT1, Compromising Anti‐Tumor Immunity

Cancer Science, EarlyView.
A20 suppresses IFN‐γ signaling in HCC cells by binding to STAT1 through its ZnF7 domain, thereby reducing CXCL9, CXCL10, and HLA‐ABC expression, ultimately impairing CD8+ T‐cell‐mediated anti‐tumor immunity. ABSTRACT Immune checkpoint blockade (ICB) has demonstrated efficacy in clinical cancer therapy; however, a significant proportion of cancer ...
Yanlei Dong, Jing Yi, Ruoxuan Yang, Yingyue Wang, Zelong Ma, Hong Yuan, Meichen Song, Ying Xiao, Chun Guo, Jianing Wang, Xiaoyan Wang, Faliang Zhu, Lining Zhang, Yuchen Fan, Yongyu Shi   +14 more
wiley   +1 more source

Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases. [PDF]

Drug Des Devel Ther
Dai R, Lou N, Zheng X, Han X.
europepmc   +1 more source

Selective Janus kinase inhibitors exhibit different effects in murine immune aplastic anemia. [PDF]

Hemasphere
Durrani J, Feng X, Wu Z, Gao S, Manley AL, Wu L, Glass J, Patel BA, Chen J, Young NS, Groarke EM.   +10 more
europepmc   +1 more source

Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series. [PDF]

Case Rep Dermatol
Zhao G, Liu Y, Ni J, Song Z.
europepmc   +1 more source